The role of mutation of metabolism-related genes in genomic hypermethylation

Biochemical and Biophysical Research Communications

Volumn 455, Issue 1-2, 2014, Pages 16-23

  Waterfall, Joshua J ^a   Killian, J Keith ^a   Meltzer, Paul S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; DNA methylation; FH; IDH; Metabolism; SDH

Indexed keywords

2 HYDROXYGLUTARIC ACID; 5 METHYLCYTOSINE; DIOXYGENASE; ISOCITRATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE; ALPHA-HYDROXYGLUTARATE; FUMARATE HYDRATASE; GLUTARIC ACID DERIVATIVE;

ASTROCYTOMA; CANCER GENETICS; CARCINOGENESIS; DNA METHYLATION; GENE FUNCTION; GENE MUTATION; GENOMICS; GLIOMA; HUMAN; METABOLISM; METABOLITE; NEOPLASM; REVIEW; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN GENOME; MUTATION;

DIOXYGENASES; DNA METHYLATION; FUMARATE HYDRATASE; GENOME, HUMAN; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASMS; SUCCINATE DEHYDROGENASE;

EID: 84912123719     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.08.003     Document Type: Review

References (116)

1. H.A. Krebs, and L.V. Eggleston The oxidation of pyruvate in pigeon breast muscle Biochem. J. 34 1940 442 459
2. O. Warburg On the origin of cancer cells Science 123 1956 309 314
3. D.W. Parsons An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
4. E.R. Mardis Recurring mutations found by sequencing an acute myeloid leukemia genome N. Engl. J. Med. 361 2009 1058 1066
5. H. Yan IDH1 and IDH2 mutations in gliomas N. Engl. J. Med. 360 2009 765 773
6. L. Dang Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
7. P.S. Ward The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 2010 225 234
8. S. Pusch Glioma IDH1 mutation patterns off the beaten track Neuropathol. Appl. Neurobiol. 37 2011 428 430
9. S. Pusch D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma Acta Neuropathol. Commun. 2 2014 19
10. R. Gupta Expanding the spectrum of IDH1 mutations in gliomas Mod. Pathol. 26 2013 619 625
11. X. Xu Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity J. Biol. Chem. 279 2004 33946 33957
12. C. Des Rosiers, C. Fernandez, F. David, and H. Brunengraber Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver. Evidence from isotopomer analysis of citric acid cycle intermediates J. Biol. Chem. 269 1994 27179 27182
13. B. Comte, G. Vincent, B. Bouchard, M. Benderdour, and C. Des Rosiers Reverse flux through cardiac NADP(+)-isocitrate dehydrogenase under normoxia and ischemia Am. J. Physiol. Heart Circ. Physiol. 283 2002 H1505 H1514
14. J.L. Gabriel, P.R. Zervos, and G.W.E. Plaut Activity of purified NAD-specific isocitrate dehydrogenase at modulator and substrate concentrations approximating conditions in mitochondria Metabolism 35 1986 661 667
15. D.T. Hartong Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle Nat. Genet. 40 2008 1230 1234
16. R. Rzem A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria Proc. Natl. Acad. Sci. U.S.A. 101 2004 16849 16854
17. M. Topçu l-2-hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1 Hum. Mol. Genet. 13 2004 2803 2811
18. E.A. Struys Mutations in the d-2-hydroxyglutarate dehydrogenase gene cause d-2-hydroxyglutaric aciduria Am. J. Hum. Genet. 76 2005 358 360
19. Y. Achouri Identification of a dehydrogenase acting on d-2-hydroxyglutarate Biochem. J. 381 2004 35 42
20. B. Nota Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined d-2- and l-2-hydroxyglutaric aciduria Am. J. Hum. Genet. 92 2013 627 631
21. M. Aghili, F. Zahedi, and E. Rafiee Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review J. Neurooncol. 91 2009 233 236
22. M. Kranendijk Evidence for genetic heterogeneity in d-2-hydroxyglutaric aciduria Hum. Mutat. 31 2010 279 283
23. R. Chowdhury The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases EMBO Rep. 12 2011 463 469
24. P. Koivunen Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation Nature 483 2012 484 488
25. J.-A. Losman (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible Science 339 2013 1621 1625
26. M. Kranendijk IDH2 mutations in patients with d-2-hydroxyglutaric aciduria Science 330 2010 336
27. H. Noushmehr Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
28. M.E. Figueroa Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 2010 553 567
29. C. Loenarz, and C.J. Schofield Expanding chemical biology of 2-oxoglutarate oxygenases Nat. Chem. Biol. 4 2008 152 156
30. N.R. Rose, M.A. McDonough, O.N.F. King, A. Kawamura, and C.J. Schofield Inhibition of 2-oxoglutarate dependent oxygenases Chem. Soc. Rev. 40 2011 4364 4397
31. W. Xu Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 2011 17 30
32. S. Zhao Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha Science 324 2009 261 265
33. S.N. Greer, J.L. Metcalf, Y. Wang, and M. Ohh The updated biology of hypoxia-inducible factor EMBO J. 31 2012 2448 2460
34. S.C. Williams R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma Acta Neuropathol. 121 2011 279 281
35. R.B. Lorsbach TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) Leukemia 17 2003 637 641
36. S. Ito Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification Nature 466 2010 1129 1133
37. M. Tahiliani Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 2009 930 935
38. W. Kim, and L.M. Liau IDH mutations in human glioma Neurosurg. Clin. N. Am. 23 2012 471 480
39. S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin. Cancer Res. 15 2009 6002 6007
40. M.J. Van den Bent MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951 Clin. Cancer Res. 19 2013 5513 5522
41. D. Sturm Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma Cancer Cell 22 2012 425 437
42. S. Turcan IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 2012 479 483
43. C. Lu IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 483 2012 474 478
44. D. Rakheja, S. Konoplev, L.J. Medeiros, and W. Chen IDH mutations in acute myeloid leukemia Hum. Pathol. 43 2012 1541 1551
45. S. Abbas Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value Blood 116 2010 2122 2126
46. O. Kosmider Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms Leukemia 24 2010 1094 1096
47. A. Tefferi IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis Leukemia 24 2010 1302 1309
48. F. Thol IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis Haematologica 95 2010 1668 1674
49. O. Kosmider TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood 114 2009 3285 3291
50. A. Tefferi TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis Leukemia 23 2009 905 911
51. P.A. Ho Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group Pediatr. Blood Cancer 57 2011 204 209
52. P.A. Ho Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study Leukemia 24 2010 909 913
53. A.K. Andersson IDH1 and IDH2 mutations in pediatric acute leukemia Leukemia 25 2011 1570 1577
54. C. Quivoron TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis Cancer Cell 20 2011 25 38
55. M. Sakata-Yanagimoto Somatic RHOA mutation in angioimmunoblastic T cell lymphoma Nat. Genet. 46 2014 171 175
56. R.A. Cairns IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma Blood 119 2012 1901 1903
57. M.S. White, P.L. Martin, and T.W. McLean Acute myelogenous leukemia associated with Ollier disease Pediatr. Blood Cancer 50 2008 645 646
58. J.P. Lawson, and G. Scott Case report 602: spindle cell hemangioendothelioma (SCH) and enchondromatosis (a form of Maffucci syndrome) in a patient with acute myelocytic leukemia (AML) Skeletal Radiol. 19 1990 158 162
59. T.C. Pansuriya, H.M. Kroon, and J.V.M.G. Bovée Enchondromatosis: insights on the different subtypes Int. J. Clin. Exp. Pathol. 3 2010 557 569
60. T.C. Pansuriya Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome Nat. Genet. 43 2011 1256 1261
61. M.F. Amary Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2 Nat. Genet. 43 2011 1262 1265
62. M.F. Amary IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours J. Pathol. 224 2011 334 343
63. C. Lu Induction of sarcomas by mutant IDH2 Genes Dev. 27 2013 1986 1998
64. P. Guilhamon Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 Nat. Commun. 4 2013 2166
65. P. Wang Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas Oncogene 32 2013 3091 3100
66. D.R. Borger Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping Oncologist 17 2012 72 79
67. W. Chan-On Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers Nat. Genet. 45 2013 1474 1478
68. V. Yankovskaya Architecture of succinate dehydrogenase and reactive oxygen species generation Science 299 2003 700 704
69. B.E. Baysal Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma Science 287 2000 848 851
70. O. Gimm, M. Armanios, H. Dziema, H.P. Neumann, and C. Eng Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma Cancer Res. 60 2000 6822 6825
71. D. Astuti Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma Am. J. Hum. Genet. 69 2001 49 54
72. J.-P. Bayley SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma Lancet Oncol. 11 2010 366 372
73. N. Burnichon SDHA is a tumor suppressor gene causing paraganglioma Hum. Mol. Genet. 19 2010 3011 3020
74. H.-X. Hao SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma Science 325 2009 1139 1142
75. S. Niemann, and U. Müller Mutations in SDHC cause autosomal dominant paraganglioma, type 3 Nat. Genet. 26 2000 268 270
76. E. Korpershoek SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas J. Clin. Endocrinol. Metab. 96 2011 E1472 E1476
77. P.B. Douwes Dekker SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology J. Pathol. 201 2003 480 486
78. P.L.M. Dahia A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas PLoS Genet. 1 2005 72 80
79. A.J. Gill Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes Hum. Pathol. 41 2010 805 814
80. F.H. Van Nederveen An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis Lancet Oncol. 10 2009 764 771
81. K.A. Janeway Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations Proc. Natl. Acad. Sci. U.S.A. 108 2011 314 318
82. M.A. Pantaleo SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing J. Natl Cancer Inst. 103 2011 983 987
83. K. Sircar Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors Am. J. Surg. Pathol. 23 1999 377 389
84. J.A. Carney, and C.A. Stratakis Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad Am. J. Med. Genet. 108 2002 132 139
85. B. Pasini Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD Eur. J. Hum. Genet. 16 2008 79 88
86. S.R. McWhinney, B. Pasini, and C.A. Stratakis Familial gastrointestinal stromal tumors and germ-line mutations N. Engl. J. Med. 357 2007 1054 1056
87. S. Vanharanta Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma Am. J. Hum. Genet. 74 2004 153 159
88. H.P.H. Neumann Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations JAMA 292 2004 943 951
89. A.J. Gill Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4 N. Engl. J. Med. 364 2011 885 886
90. C. Ricketts Germline SDHB mutations and familial renal cell carcinoma J. Natl Cancer Inst. 100 2008 1260 1262
91. A.S. Hoekstra, and J.-P. Bayley The role of complex II in disease Biochim. Biophys. Acta 1827 2013 543 551
92. A. Levitas Familial neonatal isolated cardiomyopathy caused by a mutation in the flavoprotein subunit of succinate dehydrogenase Eur. J. Hum. Genet. 18 2010 1160 1165
93. T. Bourgeron Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency Nat. Genet. 11 1995 144 149
94. C.L. Alston Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency J. Med. Genet. 49 2012 569 577
95. D. Ghezzi SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy Nat. Genet. 41 2009 654 656
96. A.P. Gimenez-Roqueplo The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway Am. J. Hum. Genet. 69 2001 1186 1197
97. N.S. Chandel Mitochondrial reactive oxygen species trigger hypoxia-induced transcription Proc. Natl. Acad. Sci. 95 1998 11715 11720
98. M.A. Selak Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase Cancer Cell 7 2005 77 85
99. M. Xiao Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors Genes Dev. 26 2012 1326 1338
100. E. Letouzé SDH mutations establish a hypermethylator phenotype in paraganglioma Cancer Cell 23 2013 739 752
101. J.K. Killian Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor Cancer Discov. 3 2013 648 657
102. B. Zbar Original articles: kidney cancer: hereditary papillary renal cell carcinoma: clinical studies in 10 families J. Urol. 153 1995 907 912
103. V. Launonen Inherited susceptibility to uterine leiomyomas and renal cell cancer Proc. Natl. Acad. Sci. U.S.A. 98 2001 3387 3392
104. I.P.M. Tomlinson Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer Nat. Genet. 30 2002 406 410
105. J.R. Toro Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America Am. J. Hum. Genet. 73 2003 95 106
106. L.J. Castro-Vega Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas Hum. Mol. Genet. 23 2014 2440 2446
107. J.S. Isaacs HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability Cancer Cell 8 2005 143 153
108. L.M. Kats Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance Cell Stem Cell 14 2014 329 341
109. J. Popovici-Muller Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo ACS Med. Chem. Lett. 3 2012 850 855
110. D. Rohle An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 340 2013 626 630
111. F. Wang Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation Science 340 2013 622 626
112. A. Borodovsky 5-Azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft Oncotarget 4 2013 1737 1747
113. L. Shen DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes J. Clin. Oncol. 28 2010 605 613
114. M. Toyota CpG island methylator phenotype in colorectal cancer Proc. Natl. Acad. Sci. 96 1999 8681 8686
115. K. Curtin, M.L. Slattery, and W.S. Samowitz CpG island methylation in colorectal cancer: past, present and future Patholog. Res. Int. 2011 2011 902674
116. L.A.E. Hughes The CpG island methylator phenotype: what's in a name? Cancer Res. 73 2013 5858 5868